These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 19441669)

  • 1. [Cognitive disturbances observed in chronic hepatitis C patients during pegylated interferon alpha and ribavirin therapy].
    Pawełczyk T; Pawełczyk A; Białkowska J; Jabłkowski M; Strzelecki D; Dworniak D; Rabe-Jabłońska J
    Psychiatr Pol; 2008; 42(6):925-41. PubMed ID: 19441669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon alpha and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients.
    Pawelczyk T; Pawelczyk A; Strzelecki D; Rabe-Jablonska J
    Gen Hosp Psychiatry; 2008; 30(6):501-8. PubMed ID: 19061675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Attention abnormalities in patients with chronic hepatitis C after pegylated interferon alpha and ribavirin treatment].
    Pawełczyk T; Białkowska J; Jabłkowski M; Pawełczyk A; Strzelecki D; Rabe-Jabłonska J; Dworniak D
    Pol Merkur Lekarski; 2008 Sep; 25(147):226-9. PubMed ID: 19112836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Depressive disorders and symptoms accompanying pegylated interferon alpha and ribavirin treatment of chronic hepatitis C patients].
    Pawełczyk T; Białkowska J; Jabłkowski M; Pawełczyk A; Strzelecki D; Rabe-Jabłońska J; Dworniak D
    Pol Merkur Lekarski; 2008 Jun; 24(144):516-20. PubMed ID: 18702333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis C in children with pegylated interferon and ribavirin: the impact of dose.
    Tufano M; Pia Cicalese M; Immacolata Spagnuolo M; Terlizzi V; Iorio R
    Acta Gastroenterol Belg; 2015; 78(1):8-11. PubMed ID: 26118572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
    Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
    Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
    Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
    Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neuropsychiatric adverse events in patients with chronic hepatitis C treated with pegylated or recombinant interferon-alpha].
    Drózdz W; Ziółkowska-Kochan M; Kozielewicz D; Dybowska D; Borkowska A; Halota W
    Przegl Epidemiol; 2008; 62(1):93-100. PubMed ID: 18536230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.
    Fontana RJ; Bieliauskas LA; Lindsay KL; Back-Madruga C; Wright EC; Snow KK; Lok AS; Kronfol Z; Padmanabhan L;
    Hepatology; 2007 May; 45(5):1154-63. PubMed ID: 17465000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ITPA gene variant may protect against anemia induced during pegylated interferon alfa and ribavirin combination treatment in Ukrainian patients with chronic hepatitis C.
    Kucherenko A; Pampukha V; Bobrova I ; Moroz L; Livshits L
    Tsitol Genet; 2015; 49(2):38-41. PubMed ID: 26030972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
    Bacon BR; Shiffman ML; Mendes F; Ghalib R; Hassanein T; Morelli G; Joshi S; Rothstein K; Kwo P; Gitlin N
    Hepatology; 2009 Jun; 49(6):1838-46. PubMed ID: 19291790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
    Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
    Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.
    Nguyen MH; Trinh HN; Garcia R; Nguyen G; Lam KD; Keeffe EB
    Am J Gastroenterol; 2008 May; 103(5):1131-5. PubMed ID: 18477343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response.
    Zeuzem S; Poordad F
    Curr Med Res Opin; 2010 Jul; 26(7):1733-43. PubMed ID: 20482242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
    Yu ML; Dai CY; Lee LP; Hsieh MY; Hou NJ; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Antivir Ther; 2006; 11(8):1015-9. PubMed ID: 17302371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.
    Balan V; Schwartz D; Wu GY; Muir AJ; Ghalib R; Jackson J; Keeffe EB; Rossaro L; Burnett A; Goon BL; Bowers PJ; Leitz GJ;
    Am J Gastroenterol; 2005 Feb; 100(2):299-307. PubMed ID: 15667486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.